06-Mar-2020 | Facts and Factors
Findings from Facts and Factors report “Insulin Market By Product Type (Pre-Mixed, Rapid Acting, Long Acting, Short-Acting, and Intermediate Acting) and By Application (Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Other): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020–2026” states that the global insulin market in 2019 is approximately USD 35.78 Billion. The market is expected to grow at a CAGR of 8.4 % and is anticipated to reach around USD 62.9 Billion by 2026.
Insulin is known as a protein hormone that is used in medication for the treatment of high blood glucose. Insulin medication is required during the treatment of diabetes-related syndromes and gestational diabetes. Insulin is used to control blood sugar levels in patients having diabetes mellitus type 1, diabetes mellitus type 2, and hyperosmolar hyperglycemic states. In all cases, insulin administration is required with exercise and medical nutrition therapy.
Browse the full “Insulin Market By Product Type (Pre-Mixed, Rapid Acting, Long Acting, Short-Acting, and Intermediate Acting) and By Application (Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Other): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020–2026" report at https://www.fnfresearch.com/insulin-market-by-product-type-pre-mixed-rapid-653
The occurrence of diabetes has increased tremendously with the rise in population across the globe. The primary factors accountable for the rise in the count of diabetic patients globally are the rising prevalence of obesity, hypertension, alcohol consumption, immigration, and insufficient healthcare services. The rising prevalence of diabetes has increased the demand for insulin which in turn has fuelled the growth of the global insulin market.
Additionally, governments across the globe are taking measures to control diabetes disease, and technological advancements in the insulin industry such as the innovation of insulin pens and low-side-effect oral medicines have also fueled the growth of the insulin market. However, the manufacturing cost and necessary regulatory requirements for the acceptance of biotechnology-derived products are possible reasons that probably could hamper the expected growth of the global human insulin market.
Among the product types, the pre-mixed is expected to continue dominance throughout the forecast period. The pre-mixed consumption is expected to reach 12524 Million ml by 2026 while acquiring more than 30 % of the global market share. Short-acting and long-acting are expected to remain the major consumed product types after the pre-mixed.
Type 1 diabetes mellitus is expected to remain the primary disease responsible for the highest consumption of insulin globally. The global consumption of insulin for type 1 diabetes mellitus is expected to reach 16203 Million ml by 2026.
Regional Overview:
Geographically, North America is expected to hold the largest market share of the global insulin market. The region is expected to witness a growth of CAGR 8.8 % during the forecast period. The growth behind the North American region is majorly driven by the United States. The Asia Pacific market is expected to be the fastest-growing market. India and China are expected to be key markets in the region with a combined share of more than 65 % in the Asia-Pacific region.
Report Scope
Report Attribute |
Details |
Market Size in 2019 |
USD35.78 Billion |
Projected Market Size in 2026 |
USD 62.9 Billion |
CAGR Growth Rate |
8.4 % CAGR |
Base Year |
2019 |
Forecast Years |
2020-2026 |
Key Market Players |
Novo Nordisk, Eli Lilly, Sanofi, Bioton, Biocon, Dongbao, Gan& Lee, The United Laboratories International Holding Limited, Wockhardt, and others. |
Key Segment |
Type, Application, and Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East &, Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
Competitive Landscape:
Major players operating in the insulin market mentioned in the report include Novo Nordisk, Eli Lilly, Sanofi, Bioton, Biocon, Dongbao, Gan& Lee, The United Laboratories International Holding Limited, Wockhardt, and Others.
This report segments the insulin machines market as follows:
Global Insulin Market: By Product Type Segmentation Analysis
- Pre-Mixed
- Rapid Acting
- Long Acting
- Short Acting
- Intermediate Acting
Global Insulin Market: By Application Segmentation Analysis
- Type 1 Diabetes Mellitus
- Type 2 Diabetes Mellitus
- Others
Global Insulin Market: Regional Segmentation Analysis
- North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Rest of the Middle East & Africa
About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Facts & Factors
A - 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: [email protected]
Web: https://www.fnfresearch.com
